High-throughput drug screens for amyotrophic lateral sclerosis drug discovery

References

• Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012 Apr;11(4):323–330.
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011 Oct 20;72(2):245–256.
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257–268.
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993 Mar 4;362(6415):59–62.
   PubMed Web of Science ®Google Scholar
• Bosco DA, Landers JE. Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets. CNS Neurol Disord Drug Targets. 2010 Dec;9(6):779–790.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006 Oct 6;314(5796):130–133.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007 May;61(5):427–434.
   PubMed Web of Science ®Google Scholar
• Song JH, Huang CS, Nagata K, et al. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther. 1997 Aug;282(2):707–714.
   PubMed Web of Science ®Google Scholar
• Debono MW, Le Guern J, Canton T, et al. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol. 1993 Apr 28;235(2–3):283–289.
   PubMed Web of Science ®Google Scholar
• He Y, Benz A, Fu T, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002 Feb;42(2):199–209.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience. 2004;125(1):191–201.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012 Mar;14(3):CD001447.
   Google Scholar
• Watanabe T, Yuki S, Egawa M, et al. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994 Mar;268(3):1597–1604.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Iwasaki Y. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse. PLoS One. 2015;10(10):e0140316.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tanaka M, Yuki S, et al. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr. 2018 Jan;62(1):20–38.
   PubMed Web of Science ®Google Scholar
• Ray SS, Nowak RJ, Brown RH Jr., et al. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3639–3644.
   PubMed Web of Science ®Google Scholar
• Nowak RJ, Cuny GD, Choi S, et al. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem. 2010 Apr 8; 53(7):2709–2718.
   PubMed Web of Science ®Google Scholar
• Rakhit R, Robertson J, Vande Velde C, et al. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med. 2007 Jun;13(6):754–759.
   PubMed Web of Science ®Google Scholar
• Rakhit R, Crow JP, Lepock JR, et al. Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem. 2004 Apr 9;279(15):15499–15504.
   PubMed Web of Science ®Google Scholar
• Ip P, Sharda PR, Cunningham A, et al. Quercitrin and quercetin 3-beta-d-glucoside as chemical chaperones for the A4V SOD1 ALS-causing mutant. Protein Eng Des Sel. 2017 Jun 1;30(6):431–440.
   PubMed Web of Science ®Google Scholar
• Saad S, Cereghetti G, Feng Y, et al. Reversible protein aggregation is a protective mechanism to ensure cell cycle restart after stress. Nat Cell Biol. 2017 Oct;19(10):1202–1213.
   PubMed Web of Science ®Google Scholar
• Esparza TJ, Wildburger NC, Jiang H, et al. Soluble Amyloid-beta Aggregates from Human Alzheimer’s disease brains. Sci Rep. 2016 Dec;5(6):38187.
   Google Scholar
• Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998 Sep 18;281(5384):1851–1854.
   PubMed Web of Science ®Google Scholar
• Anzai I, Toichi K, Tokuda E, et al. Screening of drugs inhibiting in vitro oligomerization of Cu/Zn-Superoxide dismutase with a mutation causing amyotrophic lateral sclerosis. Front Mol Biosci. 2016;3:40.
   PubMedGoogle Scholar
• Zinman L, Sadeghi R, Gawel M, et al. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008 Aug;9(4):223–228.
   PubMed Web of Science ®Google Scholar
• Su XW, Nandar W, Neely EB, et al. Statins accelerate disease progression and shorten survival in SOD1(G93A) mice. Muscle Nerve. 2016 Aug;54(2):284–291.
   PubMed Web of Science ®Google Scholar
• Karam C, Barrett MJ, Imperato T, et al. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J Clin Neurosci. 2013 Nov;20(11):1550–1553.
   PubMed Web of Science ®Google Scholar
• Solomon JA, Gianforcaro A, Hamadeh MJ. Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis. PLoS One. 2011;6(12):e29354.
   PubMed Web of Science ®Google Scholar
• Nishitoh H, Kadowaki H, Nagai A, et al. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 2008 Jun 1;22(11):1451–1464.
   PubMed Web of Science ®Google Scholar
• Tsuburaya N, Homma K, Higuchi T, et al. A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model. Nat Commun. 2018 Jul 10;9(1):2668.
   PubMedGoogle Scholar
• Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006 Dec 22;351(3):602–611.
   PubMed Web of Science ®Google Scholar
• Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017 Oct;5(3):17071.
   Google Scholar
• Oberstadt M, Stieler J, Simpong DL, et al. TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole. Sci Rep. 2018 Feb 2;8(1):2248.
   PubMedGoogle Scholar
• Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 1996 May;13(1):43–47.
   PubMed Web of Science ®Google Scholar
• Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 1995 Apr 3;676(1):25–40.
   PubMed Web of Science ®Google Scholar
• Nagai M, Aoki M, Miyoshi I, et al. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci. 2001 Dec 1;21(23):9246–9254.
   PubMed Web of Science ®Google Scholar
• Broom WJ, Auwarter KE, Ni J, et al. Two approaches to drug discovery in SOD1-mediated ALS. J Biomol Screen. 2006 Oct;11(7):729–735.
   PubMedGoogle Scholar
• Murakami G, Inoue H, Tsukita K, et al. Chemical library screening identifies a small molecule that downregulates SOD1 transcription for drugs to treat amyotrophic lateral sclerosis. J Biomol Screen. 2011 Apr;16(4):405–414.
   PubMedGoogle Scholar
• Wright PD, Wightman N, Huang M, et al. A high-throughput screen to identify inhibitors of SOD1 transcription. Front Biosci (Elite Ed). 2012 Jun 1;4:2701–2708.
   PubMedGoogle Scholar
• Corcoran LJ, Mitchison TJ, Liu Q. A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr Biol. 2004 Mar 23;14(6):488–492.
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009 Feb 27;323(5918):1208–1211.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJ Jr., Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009 Feb 27;323(5918):1205–1208.
   PubMed Web of Science ®Google Scholar
• Boyd JD, Lee P, Feiler MS, et al. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J Biomol Screen. 2014 Jan;19(1):44–56.
   PubMedGoogle Scholar
• Marrone L, Poser I, Casci I, et al. Isogenic FUS-eGFP iPSC reporter lines enable quantification of fus stress granule pathology that is rescued by drugs inducing autophagy. Stem Rep. 2018 Feb 13;10(2):375–389.
   PubMed Web of Science ®Google Scholar
• Burkhardt MF, Martinez FJ, Wright S, et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci. 2013;56:355–364.
   PubMed Web of Science ®Google Scholar
• Colombrita C, Zennaro E, Fallini C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009 Nov;111(4):1051–1061.
   PubMed Web of Science ®Google Scholar
• Dormann D, Rodde R, Edbauer D, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. Embo J. 2010 Aug 18;29(16):2841–2857.
   PubMed Web of Science ®Google Scholar
• Liu-Yesucevitz L, Bilgutay A, Zhang YJ, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One. 2010 Oct 11;5(10):e13250.
   PubMed Web of Science ®Google Scholar
• Yr L, King OD, Shorter J, et al. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013 Apr 29;201(3):361–372.
   PubMed Web of Science ®Google Scholar
• Ferraiuolo L, Kirby J, Grierson AJ, et al. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 Nov;7(11):616–630.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005 Jan 6;433(7021):73–77.
   PubMed Web of Science ®Google Scholar
• Colton CK, Kong Q, Lai L, et al. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J Biomol Screen. 2010 Jul;15(6):653–662.
   PubMedGoogle Scholar
• de Carvalho M, Pinto S, Costa J, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 Oct;11(5):456–460.
   PubMed Web of Science ®Google Scholar
• Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 May 3;11(3):266–271.
   PubMed Web of Science ®Google Scholar
• Berry JD, Shefner JM, Conwit R, et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013;8(4):e61177.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 Nov;13(11):1083–1091.
   PubMed Web of Science ®Google Scholar
• Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010 Mar 1;48(5):629–641.
   PubMed Web of Science ®Google Scholar
• Barber SC, Higginbottom A, Mead RJ, et al. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic Biol Med. 2009 Apr 15;46(8):1127–1138.
   PubMed Web of Science ®Google Scholar
• Mead RJ, Higginbottom A, Allen SP, et al. S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;61:438–452.
   PubMed Web of Science ®Google Scholar
• Writing Group On Behalf Of The Edaravone Als 19 Study G. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):55–63.
   PubMedGoogle Scholar
• Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007 Aug;322(2):709–720.
   PubMed Web of Science ®Google Scholar
• Lenglet T, Lacomblez L, Abitbol JL, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014 Mar;21(3):529–536.
   PubMed Web of Science ®Google Scholar
• Benmohamed R, Arvanites AC, Kim J, et al. Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Mar;12(2):87–96.
   PubMed Web of Science ®Google Scholar
• Yang YM, Gupta SK, Kim KJ, et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell. 2013 Jun 6;12(6):713–726.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 Nov 30;131(5):861–872.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663–676.
   PubMed Web of Science ®Google Scholar
• Mertens J, Marchetto MC, Bardy C, et al. Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. Nat Rev Neurosci. 2016 Jul;17(7):424–437.
   PubMed Web of Science ®Google Scholar
• Vierbuchen T, Ostermeier A, Pang ZP, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010 Feb 25;463(7284):1035–1041.
   PubMed Web of Science ®Google Scholar
• Pang ZP, Yang N, Vierbuchen T, et al. Induction of human neuronal cells by defined transcription factors. Nature. 2011 May 26;476(7359):220–223.
   PubMed Web of Science ®Google Scholar
• Meyer K, Ferraiuolo L, Miranda CJ, et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):829–832.
   PubMed Web of Science ®Google Scholar
• Neumann M, Kwong LK, Sampathu DM, et al. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch Neurol. 2007 Oct;64(10):1388–1394.
   PubMedGoogle Scholar
• Fujimori K, Ishikawa M, Otomo A, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med.2018. Oct;24:1579-1589 .
   Google Scholar
• Patten SA, Parker JA, Wen XY, et al. Simple animal models for amyotrophic lateral sclerosis drug discovery. Expert Opin Drug Discov. 2016 Aug;11(8):797–804.
   PubMed Web of Science ®Google Scholar
• Patten SA, Aggad D, Martinez J, et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight. 2017 Nov 16;2(22):1-20.
   PubMed Web of Science ®Google Scholar
• Joardar A, Menzl J, Podolsky TC, et al. PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. Hum Mol Genet. 2015 Mar 15;24(6):1741–1754.
   PubMed Web of Science ®Google Scholar
• McGown A, Shaw DP, Ramesh T. ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis. Mol Neurodegener. 2016;11(1):56.
   PubMedGoogle Scholar
• van Eijk RPA, Jones AR, Sproviero W, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017 Oct 31;89(18):1915–1922.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013 May;12(5):435–442.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018 Feb 13;90(7):e565–e74.
   PubMed Web of Science ®Google Scholar
• Lange DJ, Shahbazi M, Silani V, et al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann Neurol. 2017 Jun;81(6):837–848.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Thomson A, Kurien C, et al. Potential new complication in drug therapy development for amyotrophic lateral sclerosis. Expert Rev Neurother. 2016 Dec;16(12):1397–1405.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MC, et al. Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012 Aug;21(1469):114–128.
   Google Scholar
• Imamura K, Izumi Y, Watanabe A, et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017 May 24;9(391).
   PubMed Web of Science ®Google Scholar
• Petrov D, Mansfield C, Moussy A, et al. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment?. Front Aging Neurosci. 2017;9:68.
   PubMed Web of Science ®Google Scholar